Novartis has agreed to pay up to $7.8 billion in a licensing deal with China-based Abogen Biosciences for global rights to an early-stage experimental autoimmune disease treatment and other RNA platform assets.

Oct 2, 2026 - 07:25
 0  0
Novartis has agreed to pay up to $7.8 billion in a licensing deal with China-based Abogen Biosciences for global rights to an early-stage experimental autoimmune disease treatment and other RNA platform assets.

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0